Erez Aminov

Chairman and Chief Executive Officer

Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company pioneering age-reversal science. Under his leadership, Telomir has advanced innovative therapies targeting age-related conditions, including Type 2 Diabetes, aging, and Progeria—a rare and fatal genetic disorder characterized by accelerated aging in children. Mr. Aminov has successfully guided Telomir through multiple preclinical trials, secured critical funding, and built a high-performing team dedicated to advancing transformative solutions in regenerative medicine.

In addition to his leadership at Telomir, Mr. Aminov serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a biopharmaceutical company developing groundbreaking treatments for neuropsychiatric disorders. At MIRA, he has been instrumental in advancing key therapies such as MIRA55 and Ketamir-2, securing funding, and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field.

With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceuticals and Telomir Pharmaceuticals, demonstrating his expertise in navigating complex regulatory and financial landscapes.

Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of strategic vision, financial expertise, and commitment to advancing life-changing therapies has positioned Telomir Pharmaceuticals at the forefront of age-reversal science.